# Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers

> **NCT05464745** · PHASE1 · COMPLETED · sponsor: **Darnitsa Pharmaceutical Company** · enrollment: 42 (actual)

## Conditions studied

- Bioequivalence
- Healthy Subjects

## Interventions

- **DRUG:** PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets
- **DRUG:** Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets

## Key facts

- **NCT ID:** NCT05464745
- **Lead sponsor:** Darnitsa Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-19
- **Primary completion:** 2021-06-09
- **Final completion:** 2021-06-09
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464745, "Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05464745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*